Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the cotext of Ruxolitinib & Vitiligo, topical ruxolitinib 1.5% cream (Opzelura TM) is approved by both the FDA and EMA for non-segmental vitiligo in patients ≥12 years (1, 2, 3, 4)
In the clinical phase II trial identified as NCT03099304, it was discovered that using ruxolitinib cream led to significant repigmentation of vitiligo lesions over a treatment period of up to 52 weeks. Additionally, all administered doses were well tolerated by the participants. This information indicates that ruxolitinib cream could potentially serve as an effective treatment option for individuals sufferin…